174 related articles for article (PubMed ID: 37695277)
21. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
22. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Lien PW; Joshi M; Tice JA; Agboola F; Nikitin D; Withanawasam V; Jatoi S; Touchette DR
J Manag Care Spec Pharm; 2024 Jun; 30(6):517-527. PubMed ID: 38824625
[TBL] [Abstract][Full Text] [Related]
24. Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment.
Mehrabyan A; Traub RE
Muscle Nerve; 2024 Apr; 69(4):467-471. PubMed ID: 38284651
[TBL] [Abstract][Full Text] [Related]
25. Efgartigimod: First Approval.
Heo YA
Drugs; 2022 Feb; 82(3):341-348. PubMed ID: 35179720
[TBL] [Abstract][Full Text] [Related]
26. Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.
Dewilde S; Qi CZ; Phillips G; Iannazzo S; Janssen MF
Adv Ther; 2023 Apr; 40(4):1818-1829. PubMed ID: 36867327
[TBL] [Abstract][Full Text] [Related]
27. Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
Yan C; Yue Y; Guan Y; Bu B; Ke Q; Duan R; Deng H; Xue Q; Jiang H; Xiao F; Yang H; Chang T; Zou Z; Li H; Tan S; Xiao H; Zhou H; Zhang H; Meng Q; Li W; Li W; Guo J; Zhang Y; Li Z; Tu J; Shi J; Li W; Lee M; Chen Y; Tao X; Zhao S; Li P; Zhao C;
JAMA Neurol; 2024 Mar; 81(4):336-45. PubMed ID: 38436998
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
[TBL] [Abstract][Full Text] [Related]
30. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
[TBL] [Abstract][Full Text] [Related]
31. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
33. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Suh J; Clarke V; Amato AA; Guidon AC
Muscle Nerve; 2022 Sep; 66(3):348-353. PubMed ID: 35684980
[TBL] [Abstract][Full Text] [Related]
34. Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report.
Wang S; Wang Q; Jin L; Dong J; Ding J
Int J Surg Case Rep; 2024 Feb; 115():109241. PubMed ID: 38219512
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
36. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective.
Suzuki S; Uzawa A; Murai H
Expert Rev Clin Immunol; 2022 Dec; 18(12):1207-1215. PubMed ID: 36227228
[TBL] [Abstract][Full Text] [Related]
37. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
Guptill JT; Sleasman JW; Steeland S; Sips M; Gelinas D; de Haard H; Azar A; Winthrop KL
Autoimmunity; 2022 Dec; 55(8):620-631. PubMed ID: 36036539
[TBL] [Abstract][Full Text] [Related]
38. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
[TBL] [Abstract][Full Text] [Related]
39. A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis.
Bril V; Silvestri NJ; Barnett-Tapia C
Prim Care Companion CNS Disord; 2022 May; 24(3):. PubMed ID: 35621832
[No Abstract] [Full Text] [Related]
40. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
